References
- Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncology 2014;16(Suppl4):iv1–63.
- Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310(17):1842-50.
- Young RM, Jamshidi A, Davis G, et al. Current trends in the surgical management and treatment of adult glioblastoma. Ann Translat Med 2015;3(9):121.
- Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life 2009;2:386-93.
- Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol 2015;22:e273-e281.
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
- AVASTIN (bevacizumab) FDA product label. 2015. Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125085s312lbl.pdf. [Last accessed July 2016].
- Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-8.
- Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma [Clinical Trial, Phase II]. J Clin Oncol Offic J Am Soc Clin Oncol 2009;27:740-5.
- Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Offic J Am Soc Clin Oncol 2009;27:4733-40.
- Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53.
- Brandes AA, Finocchiaro G, Zagonel V, et al. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-oncology 2016;18:1304-12.
- Wick W, Stupp R, Gorlia T, et al. Phase II part of EORTC study 26101: the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. J Clin Oncol Offic J Am Soc Clin Oncol 2016;34(15suppl2019):2019-2019.
- van den Bent M, Gorlia T, Bendszus M, et al. EH1.3EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma. Neuro-oncology 2016;18(Suppl4):iv1-iv2.
- Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer 2013;119:3489-95.
- Wachtel MS, Yang S. Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. Cancer Med 2014;3:660-6.
- Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-22.
- Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) Research Data (1973-2012), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2015, based on the December 2012 submission.
- Girvan AC, Carter GC, Li L, et al. Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA. Drugs in Context 2015;4:212274.
- Gilbert MR. Antiangiogenic therapy for glioblastoma: complex biology and complicated results. J Clin Oncol Offic J Am Soc Clin Oncol 2016;34:1567-9.
- Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
- Field KM, Jordan JT, Wen PY, et al. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer 2015;121:997-1007.
- Theeler BJ, Gilbert MR. Advances in the treatment of newly diagnosed glioblastoma. BMC Med 2015;13:293.
- Liu TT, Achrol AS, Mitchell LA, et al. Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro-oncology 2016;270.
- Darefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 2012;118:2163-72.
- FDA News Release. FDA approves new medical device for form of brain cancer. 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm. [Last accessed August 2016].